Search research articles
Contact Us
Filters
Showing results (561-570 of 651) with videos related to
Page
of 66
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
December 21, 2004
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models
Gene G Kinney, Julie A O'Brien, Wei Lemaire, et al.
The Medical Journal of Australia
|
October 5, 2020
Outcomes for children after second liver transplantations are similar to those after first transplantations: a binational registry analysis
Angus W Jeffrey, Gary P Jeffrey, Michael Stormon, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 13, 2012
Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold
Alice L Rodriguez, Ya Zhou, Richard Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice
Tristano Pancani, Daniel J Foster, Mark S Moehle, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 1, 2018
Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu<sub>4</sub> positive allosteric modulators that mitigate CYP1A2 induction liability
Darren W Engers, Sean R Bollinger, Julie L Engers, et al.
Hepatology (Baltimore, Md.)
|
December 20, 2014
The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial
Leon A Adams, Darrell H Crawford, Katherine Stuart, et al.
Journal of Medicinal Chemistry
|
September 4, 2015
Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents
Julie L Engers, Alice L Rodriguez, Leah C Konkol, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 18, 2015
Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound
Ya Zhou, Chrysa Malosh, Susana Conde-Ceide, et al.
ACS Medicinal Chemistry Letters
|
October 24, 2017
Discovery of VU6005649, a CNS Penetrant mGlu<sub>7/8</sub> Receptor PAM Derived from a Series of Pyrazolo[1,5-<i>a</i>]pyrimidines
Masahito Abe, Mabel Seto, Rocco G Gogliotti, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2
Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
Page
of 66
Search research articles
Search
Showing results (561-570 of 651) with videos related to
Sort By:
Page
of 66
The Journal of Pharmacology and Experimental Therapeutics
|
December 21, 2004
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models
Gene G Kinney, Julie A O'Brien, Wei Lemaire, et al.
The Medical Journal of Australia
|
October 5, 2020
Outcomes for children after second liver transplantations are similar to those after first transplantations: a binational registry analysis
Angus W Jeffrey, Gary P Jeffrey, Michael Stormon, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 13, 2012
Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold
Alice L Rodriguez, Ya Zhou, Richard Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice
Tristano Pancani, Daniel J Foster, Mark S Moehle, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 1, 2018
Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu<sub>4</sub> positive allosteric modulators that mitigate CYP1A2 induction liability
Darren W Engers, Sean R Bollinger, Julie L Engers, et al.
Hepatology (Baltimore, Md.)
|
December 20, 2014
The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial
Leon A Adams, Darrell H Crawford, Katherine Stuart, et al.
Journal of Medicinal Chemistry
|
September 4, 2015
Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents
Julie L Engers, Alice L Rodriguez, Leah C Konkol, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 18, 2015
Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound
Ya Zhou, Chrysa Malosh, Susana Conde-Ceide, et al.
ACS Medicinal Chemistry Letters
|
October 24, 2017
Discovery of VU6005649, a CNS Penetrant mGlu<sub>7/8</sub> Receptor PAM Derived from a Series of Pyrazolo[1,5-<i>a</i>]pyrimidines
Masahito Abe, Mabel Seto, Rocco G Gogliotti, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2
Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
Page
of 66